3542-72-1Relevant articles and documents
An Improved C-Deglycosylation of Mangiferin to Norathyriol
Ahn, Sungwan,Yun, Hwayoung,Han, Young Taek
, p. 91 - 94 (2018)
-
A novel and efficient synthesis of norathyriol using Pd(II) as a catalyst
Qin, Qi-Xue,Yang, Jian,Yang, Bo
, p. 1633 - 1636 (2014)
A facile and simple procedure for the synthesis of norathyriol using Pd(II) as a catalyst via two steps under mild conditions is described. The major advantages of this method are the use of a commercially available catalyst, short reaction times, and the simplicity of the reaction and work-up. The overall yield of 36.6 % is acceptable.
-
Haynes,Taylor
, p. 1685 (1966)
-
Studies on the constituents of Swertia japonica. V. On the xanthone constituents of the plants of Swertia ssp
Tomimori,Komatsu
, p. 410 - 417 (1969)
-
Design, synthesis, and biological evaluation of 1,3,6,7-tetrahydroxyxanthone derivatives as phosphoglycerate mutase 1 inhibitors
Jiang, Kaixuan,Gao, Biao,Yu, Jing,Jiang, Lulu,Niu, Ao,Jia, Yihe,Meng, Tao,Zhou, Lu,Wang, Jinxin
, (2021/02/09)
Phosphoglycerate mutase 1 (PGAM1) is a promising target for cancer treatment. Herein, we found that α-mangostin and γ-mangostin exhibited moderate PGAM1 inhibitory activities, with IC50 of 7.2 μM and 1.2 μM, respectively. Based on α-mangostin, a series of 1,3,6,7-tetrahydroxyxanthone derivatives were designed, synthesized and evaluated in vitro for PGAM1 inhibition. The significant structure–activity relationships (SAR) and a fresh binding mode of this kind of new compounds were also clearly described. This study provides valuable information for further optimization of PGAM1 inhibitors with 1,3,6,7-tetrahydroxyxanthone backbone or de novo design of novel inhibitor.
Synthesis of xanthone derivatives and studies on the inhibition against cancer cells growth and synergistic combinations of them
Liu, Jie,Zhang, Jianrun,Wang, Huailing,Liu, Zhijun,Zhang, Cao,Jiang, Zhenlei,Chen, Heru
, p. 50 - 61 (2017/04/06)
34 Xanthones were synthesized by microwave assisted technique. Their in?vitro inhibition activities against five cell lines growth were evaluated. The SAR has been thoroughly discussed. 7-Bromo-1,3-dihydroxy-9H-xanthen-9-one (3-1) was confirmed as the most active agent against MDA-MB-231?cell line growth with an IC50 of 0.46?±?0.03?μM. Combination of 3-1 and 5,6-dimethylxanthone-4-acetic acid (DMXAA) showed the best synergistic effect. Apoptosis analysis indicated different contributions of early/late apoptosis and necrosis to cell death for both monomers and the combination. Western Blot implied that the combination regulated p53/MDM2 to a better healthy state. Furthermore, 3-1 and DMXAA arrested more cells on G2/M phase; while the combination arrested more cells on S phase. All the evidences support that the 3-1/DMXAA combination is a better anti-cancer therapy.